<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/311A7425-EF0A-4690-8AFD-5FC746DC41AD"><gtr:id>311A7425-EF0A-4690-8AFD-5FC746DC41AD</gtr:id><gtr:name>Vancouver Prostate Centre (VPC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AAA885A1-F572-4D99-AD80-668C14A7DABF"><gtr:id>AAA885A1-F572-4D99-AD80-668C14A7DABF</gtr:id><gtr:name>University of Edinburgh, MRC Centre for Reproductive Health</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Surgery and Cancer</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/311A7425-EF0A-4690-8AFD-5FC746DC41AD"><gtr:id>311A7425-EF0A-4690-8AFD-5FC746DC41AD</gtr:id><gtr:name>Vancouver Prostate Centre (VPC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AAA885A1-F572-4D99-AD80-668C14A7DABF"><gtr:id>AAA885A1-F572-4D99-AD80-668C14A7DABF</gtr:id><gtr:name>University of Edinburgh, MRC Centre for Reproductive Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FD707A7C-8438-49EC-8F27-C5A46955E15A"><gtr:id>FD707A7C-8438-49EC-8F27-C5A46955E15A</gtr:id><gtr:firstName>Charlotte</gtr:firstName><gtr:otherNames>Lynne</gtr:otherNames><gtr:surname>Bevan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8524F630-A91D-4A6B-ABEE-87DD63B3194E"><gtr:id>8524F630-A91D-4A6B-ABEE-87DD63B3194E</gtr:id><gtr:firstName>Eric</gtr:firstName><gtr:surname>Aboagye</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0700915"><gtr:id>11DB3693-0CC2-47D5-A7F8-1596FA9A4668</gtr:id><gtr:title>Engineering and application of models for in vivo imaging of androgen receptor activity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700915</gtr:grantReference><gtr:abstractText>Androgens are the male sex hormones - the major androgen is testosterone. They are pivotal for male fertility and responsible for masculinisation of genitalia. However, they are also required for female fertility; and in both sexes they are important for bone development and act on the brain, heart, fat and hair follicles. Disorders associated with too much or too little androgen action are common. Severe defects can cause a genetic male to become undervirilised or even female in appearance. Less severe deficiencies, even the fall in testosterone associated with aging, can lead to male infertility, decreased muscle, weight gain and depression. Conversely, excess androgen action has been linked to Polycystic Ovarian Syndrome, female infertility, acne, baldness prostate cancer, and behavioural disorders. Patients are often treated with androgen replacement therapy or antiandrogens (which oppose androgen action). However, due to the number of possible target tissues these almost invariably produce side effects. These can include reduced sperm count, jaundice, changes in libido, hirsutism, acne, osteoporosis and increased risk of certain cancers. New therapies are constantly being developed with the aim of reducing these ?off-target? effects, while male contraceptives and HRT are being developed containing androgens. It is therefore vital we learn more about where and when these act in the body. Knowledge of their sites of action will enable tailoring of such therapies to reduce side-effects.

Androgens act by binding to androgen receptor protein, which In turn binds to specific DNA sequences (androgen response elements) in target genes, increasing the activity of these genes, which then causes growth or function of the relevant tissue. This project will exploit this by linking an androgen response element to a ?reporter? gene, activity of which can be easily detected by scanning. This activation will be detected, accurately located and measured by state-of-the-art 3-dimensional scanners uniquely available at Imperial College. We will use the system to determine where and when natural androgens are active in males and females ? this may highlight previously unknown sites of androgen action. We will also follow activation or inhibition of androgen signalling by known and novel therapeutic agents, including androgens, antiandrogens and novel therapies. As well as increasing knowledge of the role of androgens in development and aging of both sexes, this project will benefit patients with all of the conditions mentioned above since it will allow evaluation of new and more specific therapies.</gtr:abstractText><gtr:technicalSummary>The many androgen target tissues include male internal and external genitalia, ovary, uterine endometrium and in both sexes bone, skeletal muscle, the CNS, adipose tissue and hair follicles. Disorders associated with excess of or deficiency in androgen action are common, including male and female infertility, pseudohermaphroditism, hypogonadism, benign and malignant prostate conditions, acne, baldness or hirsutism, sexual desire disorders and depression. Patients are often treated with androgens or antiandrogens as appropriate, but due to the number of targets these almost invariably produce side-effects. Androgens can exacerbate prostate conditions, suppress spermatogenesis and cause jaundice, hirsutism and acne. Antiandrogen therapy is associated with hepatic tumours, osteoporosis, loss of libido, impotence and gynaecomastia. 

The major circulating androgen is testosterone, secreted by the testes, and in many target tissues this is converted to the more potent dihydrotestosterone. Both of these as well as weak adrenal androgens signal via the androgen receptor a ligand-activated transcription factor. This binds to specific response elements in the promoters of target genes and activates transcription of genes involved in growth and/or differentiation. We aim to exploit this by creating expression cassettes containing (i) the luciferase gene or (ii) the sodium iodide symporter gene under the control of an androgen response element, and create in vivo models expressing these reporters in all tissues. These will be used to visualize where and when the androgen receptor signalling pathway is activated in response to endogenous androgens during development and aging. Exogenous androgens, antiandrogens and selective AR modulators with therapeutic possibilities will also be tested under conditions mimicking those found in patients. Knowledge of their sites of action will predict possible side-effects hence suitability or limitations for therapy. Since imaging will be by non-invasive scanning using (i) luciferase imaging and (ii) more quantitative and accurate Positron Emission Tomography scanning for sodium iodide symporter activity, studies will be longitudinal and in real time. This study will increase knowledge of the role of androgens in differentiation, development and fertility of both sexes. Further, proposed crosses with models deficient in genes involved in androgen signalling will differentiate between the developmental actions of the major androgens testosterone and dihydrotestosterone, and elucidate crosstalk between androgen receptor and other steroid receptors. The model will also lend itself to many downstream applications such as the investigation of effects of hormonal environmental pollutants, androgen action in female fertility, and sexual dichotomy in obesity.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>388292</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh, MRC Centre for Reproductive Health</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Edinburgh Reproductive Sciences</gtr:description><gtr:id>3239A845-750C-4D06-9AB1-57B4496E4C38</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>Will provide expertise for reproductive research</gtr:partnerContribution><gtr:piContribution>Will provide ARE-luc mice for collaborative research</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vancouver Prostate Centre (VPC)</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Rennie collaboration</gtr:description><gtr:id>BB626881-132A-4426-9500-FB0DD2F0FDEA</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>New AR inhibitors and signalling experitse</gtr:partnerContribution><gtr:piContribution>ARE-luc mouse and imaging expertise</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talk at Queen's University Belfast</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6334475A-6494-49F2-944B-760AD2C10C3F</gtr:id><gtr:impact>talk sparked questions and discussion afterwards.

New contacts made with QUB researchers</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at Aberdeen Uni</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5A575151-BF5A-480D-BA19-7E297732FA67</gtr:id><gtr:impact>talk sparked questions and discussion afterwards.

Asked to be external examiner for student</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Donor visits</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E4EC513C-0C62-4A66-BC5F-610C143288A4</gtr:id><gtr:impact>Between 3 and 12 lay people who donate to charities funding cancer research attended the dept for a lab tour and talks describing the kind of research we undertake and its implications.

Donors pledged funding either in general or for other projects ongoing</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Selected talk at Androgens 016 by AD</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F6A456ED-EBC2-4573-A93E-7F6EC14E1F42</gtr:id><gtr:impact>Talk at international conference, followed by discussion with interested attendees</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prostate Cancer National Research Conference for stakeholders</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DF97ED01-B462-43D8-A57E-B75D145C8AAB</gtr:id><gtr:impact>Over 300 patients/carers/health professionals attended a research day at which members of the group had a &amp;quot;stall&amp;quot; for informal discussion of their research

Excellent feedback was received which the Prostate Cancer Charity is currently evaluating. This may become a regular event</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Endocrinology conference (Edinburgh)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5E7393FA-490C-47BC-AC19-66B327E748B3</gtr:id><gtr:impact>Postdoctoral research associate rpesented poster at the British Endocrine Society 2015</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.endocrine-abstracts.org/ea/0038/ea0038p161.htm</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lab tour and related online video by Movember/Norhampton Saints</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CBF8A3D8-3E79-4302-A6F4-8D4C313BE894</gtr:id><gtr:impact>Lab visit by funders (Movember) and supporter (Rugby personalities), plus charity Prostate cancer UK. Filming, online video, press releases</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seminar at CARDIFF UNI</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B70CDC76-A915-41C8-862D-1D291C76F59E</gtr:id><gtr:impact>Talk, followed by afternoon of discussion with interested attendees</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual Meeting of ARTP, the French Association for Prostate Cancer Research</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B05E33EF-7B50-4773-ACF0-518C9A726B48</gtr:id><gtr:impact>Questions and much discussion

Several approaches from people interested in collabroating</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.iartp.org/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference - Androgens 2014: Precision Medicines Targeting Androgen Signalling</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CE0A4E5D-AA4D-44CB-BE85-E4FD154E8046</gtr:id><gtr:impact>2 days of talks and discussion, Speakers and attendees from UK, Europe, USA, Australia, Canada. Work funded by relevant grants was presented both orally and as poster

Collaborations initiated regarding ARE-luc mouse. Ditto for Prohibitin. Industrial involvement in repressors project</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.precisionmedicines.com/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Selected talk at Androgens 2016 by AB</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C49CE5A4-CF00-4032-AEE1-8BC556E467B5</gtr:id><gtr:impact>Talk at international conference, followed by discussion with audience and ongoing discussion with interested attendees</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lab tours</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D7A57D3A-4D8B-48F0-92B5-A9218FCAA3D5</gtr:id><gtr:impact>Lab tours, with demonstrations including hand-on activities, plus a talk on our research to lay audience and quesiton session</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2011,2012,2013,2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>212000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:fundingRef>PG13-033</gtr:fundingRef><gtr:id>3EF976C5-C8CD-4A44-83A9-51B3DAD6C5B6</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>3Rs committee of Imperial College</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>5F7FEE63-7712-4DD0-A9A7-D281E1BF82E1</gtr:id><gtr:type>Participation in advisory committee</gtr:type><gtr:url>http://www3.imperial.ac.uk/research/animal-research</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Transgenic mice expressing androgen-responsive luciferase reporter gene in all tissues</gtr:description><gtr:id>0F0EF55C-8044-4EC5-B183-7A09FB92B6B9</gtr:id><gtr:impact>Paper published (Dart et al, PLOS one, 2013)</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ARE-Luc mouse model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:url>http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0071694</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>MCF breast cancer cell line in which it is possible to express a protein of interest under control of tetracycline</gtr:description><gtr:id>877F39BD-9532-493A-9D5A-4B4E6A5AD09D</gtr:id><gtr:impact>NOne as yet</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MCF7/TREx</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Prostate cancer cells with integrated luciferase reporter plus doxycycline-inducible expression of prohibitin cDNA, suitable for use in cell culture in as xenografts</gtr:description><gtr:id>56CB6290-B73B-4133-8B55-D4540DF51447</gtr:id><gtr:impact>By allowing in vivo imaging of live mice throughout tumour progression reduces numbers of animals required.
Demonstrated that increased prohibitin levels results in decreased growth of prostate tumours, hence proof of principle that increasing prohibitin levels could be a valid therapeutic strategy.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>LNCaP/Luc/PHB-cDNA</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Prostate cancer cells with integrated luciferase reporter plus doxycycline-inducible expression of prohibitin siRNA resulting in knockdown of PHB protein, suitable for use ionc ell culture in as xenografts</gtr:description><gtr:id>04110A89-EFA6-48EC-8C52-A3BD2B475AE6</gtr:id><gtr:impact>By allowing in vivo imaging of live mice throughout tumour progression reduces numbers of animals required.
Demonstrated that decreased prohibitin levels results in increased growth of prostate tumours, hence proof of the hypothesis that decreasing amounts of corepressor proteins could lead to tumour progression.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>LNCaP/Luc/PHB-siRNA</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A prostate cancer cell line with an integrated androgen-responsive luciferase reporter gene, allowing in vitro and in vivo (xenograft) imaging of androgen receptor activity</gtr:description><gtr:id>6643F480-1C92-4C62-87F8-87C8B7B37719</gtr:id><gtr:impact>This allows the cell line to be used to detect androgen signalling in xenografts in living animals by in vivo imaging, throughout up to 36 days (in our experiments) this reducing the numbers of animals required. It could be used to monitor the effects of molecules or comounds aimed at the androgen signalling pathway</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>LNCaP/Luc</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8728603E-FCFD-4153-8372-63E2A79D430F"><gtr:id>8728603E-FCFD-4153-8372-63E2A79D430F</gtr:id><gtr:title>Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fb05bb40e92b3381674f4408a8fbc08"><gtr:id>3fb05bb40e92b3381674f4408a8fbc08</gtr:id><gtr:otherNames>Dart DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C11A88F-95E6-48B8-B324-901E24CAF336"><gtr:id>3C11A88F-95E6-48B8-B324-901E24CAF336</gtr:id><gtr:title>In Vivo Imaging of Nuclear Receptor Transcriptional Activity.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fb05bb40e92b3381674f4408a8fbc08"><gtr:id>3fb05bb40e92b3381674f4408a8fbc08</gtr:id><gtr:otherNames>Dart DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:isbn>978-1-4939-3722-6</gtr:isbn><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E29FE83D-AC15-4F5C-9B6D-93768573F290"><gtr:id>E29FE83D-AC15-4F5C-9B6D-93768573F290</gtr:id><gtr:title>Visualising androgen receptor activity in male and female mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fb05bb40e92b3381674f4408a8fbc08"><gtr:id>3fb05bb40e92b3381674f4408a8fbc08</gtr:id><gtr:otherNames>Dart DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0CCE893C-5B85-451D-AE0C-19119FDCE078"><gtr:id>0CCE893C-5B85-451D-AE0C-19119FDCE078</gtr:id><gtr:title>Visualising androgen receptor activity in male and female mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fb05bb40e92b3381674f4408a8fbc08"><gtr:id>3fb05bb40e92b3381674f4408a8fbc08</gtr:id><gtr:otherNames>Dart DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7A17BA45-4938-4EA3-8ABC-426A842404E8"><gtr:id>7A17BA45-4938-4EA3-8ABC-426A842404E8</gtr:id><gtr:title>FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ac494d475208dcbe97475e9b9d7b64fd"><gtr:id>ac494d475208dcbe97475e9b9d7b64fd</gtr:id><gtr:otherNames>Brooke GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/137249A4-3EE9-42CD-9645-48C3D1AE9FF9"><gtr:id>137249A4-3EE9-42CD-9645-48C3D1AE9FF9</gtr:id><gtr:title>Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.</gtr:title><gtr:parentPublicationTitle>Endocrine-related cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fb05bb40e92b3381674f4408a8fbc08"><gtr:id>3fb05bb40e92b3381674f4408a8fbc08</gtr:id><gtr:otherNames>Dart DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1351-0088</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/976110DC-8124-4437-9835-0387B8EB887A"><gtr:id>976110DC-8124-4437-9835-0387B8EB887A</gtr:id><gtr:title>Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ac494d475208dcbe97475e9b9d7b64fd"><gtr:id>ac494d475208dcbe97475e9b9d7b64fd</gtr:id><gtr:otherNames>Brooke GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F0993767-0180-4D2C-B7C5-4545524EFD52"><gtr:id>F0993767-0180-4D2C-B7C5-4545524EFD52</gtr:id><gtr:title>Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9963549c9264179d9b975276200bffc6"><gtr:id>9963549c9264179d9b975276200bffc6</gtr:id><gtr:otherNames>Fletcher CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EF34E4B5-97A4-4AE4-9E3F-9B1A4CF6F86A"><gtr:id>EF34E4B5-97A4-4AE4-9E3F-9B1A4CF6F86A</gtr:id><gtr:title>WOMEN IN CANCER PROFILE: A gender agenda?</gtr:title><gtr:parentPublicationTitle>Endocrine-related cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/acdfff1caca1bcf8374cfed7c3c1e06f"><gtr:id>acdfff1caca1bcf8374cfed7c3c1e06f</gtr:id><gtr:otherNames>Bevan CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1351-0088</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700915</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>